DURECT stock: buy or sell?
September 20th, 2019
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and drug delivery programs.
Should I buy DURECT stock?You can't be a successful trader if you don't follow a methodolgy or system that assist you in choosing companies and the correct market timing. Trading strategies are meant for helping you in the decision process of what stocks to choose and when is the best moment to buy them. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.
Only 1 of our buy setups matches with DURECT stock now:
|New all-time high||No|
|New 52 week high||Yes|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is DURECT stock a buy?
Financial institutions and banks post stock ratings everyday.At Stocks2.com, we gathered 4 ratings published for DRRX stock in the last month. The general sentiment of these ratings is bullish for DRRX stock, with 3 positive ratings.
|Date||Analyst / Broker||Previous rating||Current rating|
DURECT stock analysis
DURECT shares boosted 12.63% to $2.14 today.
Shares of DURECT ended today at $2.14 and boosted an extraordinary 12.63%. Since last Aug/15 when SMA100d and SMA200d crossed up, DRRX price gained $0.83 per share (63.36%). Since price and SMA200d lines crossed up on July, DRRX climbed $1.47 (219.40%). From a daily perspective, DRRX is in a short term uptrend after plotting its last bottom ($1.66, on September/12) higher than the previous bottom, and its last top ($2.00, on Tuesday) also over the previous top. Now trading in between its last bottom and last top DRRX might consolidate in a plain range, waiting to break out over $2.00 or down under $1.66.
Shares of DURECT boosted an astounding 22.29% this week. By mid August DRRX collapsed a dreadful -5.88% in just one week.
Price finally broke over the resistance at $0.76 and continued climbing. Early August, SMA20w and SMA40w crossed up triggering a rise of 71.20%. Since mid July when DRRX stock price broke up the SMA40w line, it gained $1.48 (224.24%).
DURECT stock price history
DURECT stock went public on September 28th, 2000 with a price of $16.751. Since then, DRRX stock lost a -87.20%, with a yearly average of -4.80%.
1: Adjusted price after possible price splits or reverse-splits.
DURECT stock historical price chart
DRRX stock reached 52-week highs today at $2.19, and all-time highs 2000-09-28 with a price of 18.5.
DURECT stock price target is $3.40Nobody can reliably foresee how stock prices may evolve in the future. However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. You should not follow the analysts' DRRX stock price predictions in the hope that they will be met as they may be wrong and not met. For the last 30 days we found 4 price targets for DRRX stock:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-9-18||Stifel Nicolaus||Raises Target||$1.50||$2.10||40%|
Financials and fundamental analysis
Earnings date and Earnings per ShareSince last March, when DURECT presented its last earnings report, it . Unfortunately, reported EPS is not yet available in our database.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn 2018, DURECT annual sales plunged a bloodcurdling -62.25% to $18.56 M USD from $49.17 marked in 2017. Aligned with this, its earnings margin (compared to revenues) collapsed to -136.40%, that is $-25.32 million.
|2013||$15 M||-||$-21.45 M-139.9%||-|
|2014||$19 M||26.56%||$-22.11 M-114.0%||3.08%|
|2015||$19 M||-1.43%||$-22.66 M-118.5%||2.50%|
|2016||$14 M||-26.66%||$-34.51 M-246.1%||52.27%|
|2017||$49 M||250.59%||$-3.70 M-7.5%||-89.29%|
|2018||$19 M||-62.25%||$-25.32 M-136.4%||585.30%|
Quarterly financial resultsDURECT posted $3.63 million in revenues for 2018-Q4, a -54.87% less compared to previous quarter. Reported quarter earnings marked $-7.30 M with a profit margin of -201.24%. Profit margin plunged a -167.46% compared to previous quarter when profit margin was -33.79%. When comparing revenues to same quarter last year, DURECT sales marked a frightening correction and plummed a -81.44%.
|2017-Q1||$5 M||-||$-8.11 M-177.5%||-|
|2017-Q2||$4 M||-5.47%||$-9.93 M-229.9%||22.44%|
|2017-Q3||$21 M||380.23%||$6.11 M29.5%||-161.54%|
|2017-Q4||$20 M||-5.82%||$8.24 M42.1%||34.76%|
|2018-Q1||$3 M||-82.15%||$-8.30 M-237.9%||-200.75%|
|2018-Q2||$3 M||-2.15%||$-7.01 M-205.4%||-15.50%|
|2018-Q3||$8 M||135.45%||$-2.72 M-33.8%||-61.28%|
|2018-Q4||$4 M||-54.87%||$-7.30 M-201.2%||168.84%|
DURECT ownershipWhen you are planning to buy shares of a stock, it's worth to check its ownership structure.
DURECT shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 3.97% of all shares.
In case of DURECT stock, 46.07% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for DRRX stock account 0.00%, no big difference from last month.
The following table compares ownership indicators for other stocks related to DURECT:
|Market cap||$410.8 M||$1.5 B||$343.5 B||$112.1 B||$1.5 B|
|Total shares||191.9 M||79.8 M||2,640.0 M||965.4 M||41.6 M|
|Float shares||166.6 M||67.8 M||2,630.0 M||796.2 M||41.4 M|
|- Institutional holdings (%)||46.1%||117.6%||69.2%||81.5%||103.6%|
|- Insider holdings (%)||4.0%||0.1%||0.1%||0.1%||0.7%|
|Shares in short selling||0.0%||0.0%||0.0%||0.0%||0.0%|
|Friday, September 20th, 2019|
|Day range||$1.90 - $2.19|
|Average true range||$0.13|
|50d mov avg||$1.37|
|100d mov avg||$1.00|
|200d mov avg||$0.83|
DURECT performanceTo better understand DURECT performance you must compare its gains with other related stocks in same sector or industry. We compared DURECT against Heron Therapeutics, , Eli Lilly and, Pacira Pharmaceuticals, Pfizer and Zogenix in the following table:
|LLYEli Lilly and||1.14%||-8.44%||11.63%|